Add-on Acquisition • Life Science

eMolecules Acquires Specs

On May 25, 2023, eMolecules acquired life science company Specs

Acquisition Context
  • This is eMolecules’ 1st transaction in the Life Science sector.
  • This is eMolecules’ 1st transaction in the Netherlands.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free


M&A Deal Summary

Date May 25, 2023
Target Specs
Sector Life Science
Buyer(s) eMolecules
Deal Type Add-on Acquisition

Target Company

Specs

Zoetermeer, Netherlands
Specs offers chemical compound management services to the life sciences industry, particularly in the European pharmaceutical, biotechnology and academic sectors, driving time and cost efficiencies for customers' large scale drug candidate screening programs. Specs was founded in 1987 and is based in Zoetermeer, Netherlands.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

eMolecules

San Diego, California, United States

Category Company
Founded 2005
Sector Software
DESCRIPTION

eMolecules provides business intelligence data and integrated ecommerce software for screening compound, chemical building blocks and primary antibody supply chains. eMolecules was founded in 2005 and is based in San Diego, California.


Deal Context for Buyer #
Overall 3 of 4
Sector: Life Science 1 of 1
Type: Add-on Acquisition 3 of 4
Country: Netherlands 1 of 1
Year: 2023 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-07 Frontier Scientific

Newark, Delaware, United States

Frontier Scientific is a contract research organization providing outsourced compound management services to Research and Development organizations worldwide. Frontier Scientific’s core competencies and services enable dramatic cost savings and improved productivity and resource allocation for companies of all sizes, from startups to large pharma. Frontier Scientific was founded in 1988 and is based in Newark, Delaware.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-09-24 Synple

Kemptthal, Switzerland

Synple specializes in automated chemical synthesis systems and solutions for small molecules drug discovery customers. Synple was formed in 2016 and is headquartered in Kemptthal, Switzerland.

Buy -